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Objectives: To describe the pharmaceutical use, health care resource utilisation patterns, and annual direct medical cost of
epilepsy as well as determining the impact of various demographic and clinical characteristics on total costs of epilepsy in
Oman.
Methods: Medical and pharmacy data were collected for 6 months on all patients aged ≥13 years attending the Sultan Qaboos
University Hospital. Unit pharmacy and medical costs were retrieved for each patient, and multiple linear regression was utilised
to analyse the impact of various demographic and clinical characteristics on total cost.
Results: A total of 486 patients were seen over the study period. Annual direct medical costs of epilepsy amounted to US$1426.
In-patient care, the antiepileptic drug (AED) lamotrigine and specialist visits, respectively, were the first, second and third most
significant predictors of total cost. Age was associated positively, and was the most significant predictor of total costs among
demographic and clinical parameters.
Conclusions: This analysis, the first economic study of epilepsy in Oman, could assist in health care allocation of scarce resources
and in pharmacoeconomic analysis of AEDs. Besides in-patient admission, our findings demonstrate that the newer drugs are
significant predictors of total cost, and hence any incremental benefits derived from them must be rigorously assessed for their
cost-effectiveness.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Epilepsy is a common and chronic neurologic dis-
order with an annual incidence of 50–100 cases per
100 000 people and an overall prevalence of between
8 and 10 per 1000 people1. The 1995 lifetime costs of
epilepsy for annual incident and prevalent cases in the
United States were estimated at $11.1 and $12.1 bil-
lion, respectively2. Epilepsy causes significant medi-
cal and social costs, and places an economic burden on
society and individuals by causing increases in health
care costs, as well as losses in employment, wages
and household work.
To our knowledge, a cost analysis of epilepsy has
never been conducted in Oman or the Arabian Penin-
sula. Studies conducted in the United States or Europe
cannot be extrapolated to this region because of ma-
jor variations in methodology. A study’s perspective
(i.e. costs involved, definition, design, and duration of
study period), may all affect the overall costs3, 4. The
inability to generalise cost data across geographic re-
gions has recently been demonstrated in a cost com-
parison study of epilepsy in eight Western European
countries. The study showed that the charges levied
to health services payers varied by as much as a fac-
tor of 24 and the cost of antiepileptic drugs (AEDs)
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varied by up to 4.4 times across countries5. This vari-
ation occurs despite the fact that the countries share
broadly similar economic and medical systems.
The Sultanate of Oman, located at the south-east part
of the Arabian Peninsula, has a population of about 2.3
million. The health care system in Oman has expanded
rapidly since 1970. Up until that time, there were only
two hospitals in the country with health care largely
provided by traditional herbal and spiritual medicine.
There are now over 60 hospitals in addition to more
than 170 government health care centres. In the last
three decades, the health care system in Oman has
developed to such an extent that the World Health
Organization, in its World Health Report 2000, rated
Oman’s health care system as 8th among 191 member
states. In addition, health care is free to all natives of
the country, as well as to expatriates working for the
government.
In this period of cost containment, cost estimates
are becoming increasingly more valuable, and are
being utilised more and more by various economic
decision-makers to plan how the scarce health re-
sources can be allocated most efficiently. The aim of
this study was to quantify, based on direct observa-
tions of real and detailed medical and pharmacy data
of adult epileptic patients, the annual direct medical
costs of epilepsy in Sultan Qaboos University Hos-
pital (SQUH), a tertiary referral hospital in Oman.
These costs are analysed from the perspective of a
governmental hospital along with the impact on cost
of various demographic, clinical and pharmaceutical
characteristics of epilepsy.
METHODS
Patient population
This was an observational study of all epileptic pa-
tients aged 13 and above, seen at SQUH in Oman
over the 6-month period of 1 January 2000 to 30 June
2000. SQUH is located within the capital area and
provides health care to at least 200 000 people. This
hospital-based approach to sampling was able to cap-
ture all epileptic patients in this area because unlike
the United States or Europe, all patients with chronic
diseases in Oman are followed-up via a hospital-based
GP or specialist (neurologist or psychiatrist). Thirteen
years of age was chosen because it is the existing
cut-off age for patients admitted in adult medical, sur-
gical and intensive care units.
Epilepsy was defined as a chronic disorder char-
acterised by recurrent and unprovoked seizures, and
was confirmed by the results of EEG, CT or MRI
testing. Patients were identified daily through in- and
out-patient registers, and pharmacy records of pre-
scriptions. Due to ethical concerns, and as a require-
ment from the Institutional Review Board, patient
confidentiality was strictly maintained.
Data collection
The data collection form included fields for health care
resource utilisation patterns, including in-patient, GP
and specialists’ visits, demographic information (age
and gender), patient status (new or known), epilepsy
type and aetiology, neurophysiological test (EEG),
neuroradiological investigations (CT, MRI), other
laboratory tests (serum AED levels, liver and kidney
function tests, and haematological investigations), as
well as pharmacy data. Seizure types were grouped as
complex partial, simple partial, tonic–clonic, absence,
myoclonic, clonic, tonic, atonic and status epilepticus
in accordance with the classification system of the In-
ternational League Against Epilepsy6. The following
aetiologies were considered: idiopathic/cryptogenic,
trauma, infection, tumour, drug-induced, stroke, sys-
temic disease, metabolic/toxic and degenerative. As
this study was purely observational, and in no way
interfered with the management of any patient, no
protocol-induced costs were considered.
Direct medical costs
Direct medical costs were collected for all epilepsy-
related health care utilisations, including in-patient
admissions, GP and specialist visits, laboratory and
radiological investigations, and costs of pharmaceuti-
cals. The costs for laboratory and radiological inves-
tigations were obtained from SQUH’s administrative
fee schedule of July 2000.
As in-patient, GP and specialist costs (per visit)
were heavily subsidised and not truly representative
of actual costs, the charges for these services were
obtained from a private hospital (Muscat Private
Hospital), where some of the specialists share staff
privileges. Drug costs were based on the year 2000
acquisition cost of drugs by the hospital. Total drug
costs were then calculated using the unit prices and
duration of prescriptions. In order to be able to com-
pare outcomes to other countries, and because the
Omani Rial was fixed to the US dollar, the total costs
were converted to US dollars by a multiplication fac-
tor of 2.56, which was the existing exchange rate at
the initiation of the study (1 January 2000).
Statistical methods
Descriptive statistics included means and relative
frequencies for continuous and categorical data,
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respectively. Outcome variables were evaluated using
parametric and nonparametric tests as appropriate.
The dependent variable was the total cost. The in-
dependent variables included demographics (age,
gender [with male as reference], patient status [with
known patient as reference]); seizure type (with partial
seizures as reference); aetiology type (with idiopathic/
cryptogenic as reference); medications (carbamaze-
pine, sodium valproate, lamotrigine, clonazepam,
phenytoin, phenobarbitone, vigabatrin, other drugs);
and hospital-based variables (length of hospital stay,
specialists visits, GP visits, EEG, CT scan and MRI).
Medications were measured as continuous variables
representing the number of times they were refilled.
Hospital-based variables were represented as the
number of times each were utilised.
The relationships were examined with multiple
linear regression, while controlling for co-linearity.
Transformations were used where necessary to nor-
malise the dependent (cost) variable that was not
normally distributed. Multiple linear regressions were
carried out first on the cost of out-patients and then
on the total aggregated patients (including in- and
out-patients). Variables were entered into the re-
gression models simultaneously. For all analyses, a
two-tailed P value <0.05 was considered statistically
significant.
A rule of thumb in multiple regression analysis7
is that there should be at least 10–30 subjects per
independent variable. With the sample size of 486,
the ratio of subjects to independent variables in this
study was 22 to 1 and well within the recommended
threshold. Statistical analyses were performed using
SPSS version 10.07 (SPSS Inc., Chicago, IL).
RESULTS
Demographic and clinical characteristics
A total of 486 epilepsy patients were seen as either
in-patients or out-patients over the 6-month study pe-
riod. The mean age of the patients was 28 years old
(28.5 years for men, 27.7 for females) with an age
range of 14–77 years. There were roughly an equal
number of males (49.8%) and females. Only 2.3% of
patients were aged 65 years or over, and 97.7% fell
between 14 and 64 years of age. Forty-eight (∼10%)
patients were newly diagnosed. A majority of pa-
tients (56.8%) suffered from generalised seizures
(tonic–clonic 50.6%, absence 0.2%, myoclonic
5.8%, tonic 0.2%). Partial seizures included complex
(41.8%) and simple partial (1.4%) in origin. The ma-
jority (80%) of seizures were idiopathic/cryptogenic
in nature. The known causes of epilepsy included
systemic disease (5.6%), trauma (5.6%), infection
Table 1: Demographic and clinical characteristics.
Characteristic Type n %
Gender Male 242 49.8
Female 244 50.2
Age (years) =<20 169 34.8
21–30 172 35.4
31–64 134 27.6
>= 65 11 2.3
Patient status New 48 9.9
Known 438 90.1
Admission status In-patient 87 8.4
Out-patient 952 91.6
Type Partial seizures 210 43.2
Generalised seizures 276 56.8
Aetiology Idiopathic/cryptogenic 389 80
Known aetiology 27 5.6
(3.9%), stroke (2.1%), metabolic/toxic (1.7%), brain
tumour (0.6%) and degenerative (0.6%) (Table 1).
Health care resource use
The number of patient visits totalled 1039. This in-
cluded 87 in-patient admissions (among a total of
53 patients), 594 specialist visits and 358 GP visits.
In-patient service utilisation between the sexes was
similar in some respects but markedly different in oth-
ers. The females were not only admitted more fre-
quently (59 vs. 28 admissions; P = 0.002), but also
spent on average nearly three times as much time in
the hospital (20.0 days vs. 7.4 days; P = 0.0263) than
the males during the study period. The overall hospi-
tal admission rate was 8.4% (87/1039 = 0.084). The
average length of hospital stay for those who were
admitted was 9.0 days. Other services (GP and spe-
cialist visits, MRI, CT and EEG) were evenly utilised
between the two genders. The patients had on average
1.22 and 0.66 specialist and GP visits, respectively.
During the 6-month period, 19.3% of patients had an
EEG while 11.3 and 3.3% of the patients had CT and
MRI scans, respectively (Tables 1 and 2).
AED refill pattern and cost
A total of 652 AEDs were prescribed during the study
period with an average of 1.34 drugs per patient. A
total of 1460 AEDs were dispensed corresponding
to an average of just over three prescription refills
per patient per 6 months. The most common AED
refill was sodium valproate (35.4%) followed by car-
bamazepine (30.8%) and lamotrigine (9.7%). All pa-
tients were prescribed at least one AED. Nearly 74%
were on monotherapy, 19% were on two AEDs, and
nearly 6% were on three or more AEDs. There were
five patients on four AEDs. The projected annual cost
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Table 2: Health care resource utilisation pattern by gender.
Characteristic Male Female Total P value
Gender 236 250 486
Age (mean ± SD) 28.5 ± 13.1 27.7 ± 12.5 28.1 ± 12.8 0.508
Hospital visits 27 60 87 0.023a
Hospital stay (days) 163 621 784 0.002a
Specialist visits 297 297 594 0.239
GP visits 161 197 358 0.436
EEG 51 51 102 0.515
CT 32 30 62 0.456
MRI 6 10 16 0.318
a Significant below 0.05 level.
Table 3: Antiepileptic drug (AED) refill utilisation pattern.
AED type Prescription refill (n = 1460) %
Carbamazepine 450 30.8
Clonazepam 119 8.2
Lamotrigine 142 9.7
Phenytoin 119 8.2
Valproate 517 35.4
Vigabatrin 18 1.2
Phenobarbitone 28 1.9
Other AEDsa 67 4.6
a Included primidone, diazepam, midazolam, topiramate and
gabapentin.
of AEDs amounted to US$156 898 with an average
of US$323 per patient per year (Table 3).
Annual direct medical cost
The total annual direct medical cost of epilepsy for
the hospital was calculated to be US$1432. The sin-
Table 4: Annual cost of epilepsy in Oman (in US dollarsa).
Resource n N Unit price ($) Total price ($) %
Hospital service
In-patient stay (days) 53 784 230 180 320 51.8
Specialist visit 319 594 77 45 738 13.1
GP visit 156 358 26 9308 2.7
Pharmaceutical
AEDs 652 1460 – 78 449 22.5
Lab investigations
Plasma AED levels 119 150 – 3511 1.0
Other investigations – – – 2249 0.6
Physiological test
EEG 94 102 77 7854 2.3
Radiological tests
CT 55 62 256 15 872 4.6
MRI 16 16 294 4704 1.4
Total cost 348 005 100.0
Total cost/patient 716
Annual cost/patient 1432
n = number of patients; N = number of resource utilisations; AED = antiepileptic drug.
a One Omani Rial = US dollars 2.56 (1 July 2000).
gle most significant and expensive contributor to to-
tal cost was in-patient utilisation, which accounted for
nearly 52% of the total cost. Pharmaceutical expen-
diture (22.5%) and specialist visits (13.2%) were the
second and third most expensive cost elements, re-
spectively (Table 4).
Cost impact of various demographic and
clinical parameters
Since the total cost was not normally distributed, a log-
arithmic computation was performed to normalise the
dependent cost variable. All tolerance values exceeded
0.1; likewise, the variance inflation factor (VIF) values
were also well below the threshold mark of 10. Both of
these results indicated that interpretation of the regres-
sion coefficients was not affected by multi-collinearity.
For out-patients, the model fit the data well (R2 =
0.762, F = 80.727, P = 0.001). The predictor that
weighed most highly on total cost was specialist visits
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Table 5: Multiple linear regressions on total cost.
Variable Modalities Beta coefficients (95% CI)
OPD (n = 472) All patients (n = 486)
Age −0.008 (−0.002, 0.001) 0.083 (0.001, 0.005)***
Gender Male, female 0.009 (−0.03, 0.044) −0.013 (−0.062, 0.036)
Patient status New, known −0.007 (−0.08, 0.063) 0.01 (−0.085, 0.12)
Epilepsy type Partial, generalised −0.078 (−0.101, −0.025)*** −0.043 (−0.094, 0.007)
Epilepsy aetiology Idio/crypto, known −0.051 (−0.099, −0.005)* 0.012 (−0.05, 0.081)
AED Carbamazepine 0.136 (0.019, 0.067)*** 0.107 (0.008, 0.069)**
Valproate 0.1 (0.008, 0.051)*** 0.112 (0.01, 0.065)**
Lamotrigine 0.372 (0.138, 0.187)*** 0.321 (0.141, 0.205)***
Clonazepam 0.001 (−0.023, 0.024) 0.021 (−0.018, 0.042)
Phenytoin 0.015 (−0.02, 0.036) 0.034 (−0.016, 0.057)
Phenobarbitone 0.011 (−0.035, 0.056) 0.007 (−0.052, 0.07)
Diazepam – 0.095 (0.238, 0.807)***
Vigabatrin 0.169 (0.158, 0.276)*** 0.142 (0.152, 0.31)***
Others 0.041 (−0.006, 0.061) 0.033 (−0.016, 0.07)
LOS – 0.472 (0.292, 0.432)***
Specialist visits 0.554 (0.154, 0.223)*** 0.267 (0.069, 0.158)***
GP visits 0.187 (0.03, 0.094)*** 0.016 (−0.035, 0.049)
EEG 0.17 (0.111, 0.231)*** 0.194 (0.144, 0.289)***
CT 0.214 (0.206, 0.349)*** 0.134 (0.093, 0.259)***
MRI 0.116 (0.169, 0.398)*** 0.062 (0.033, 0.311)**
Model fit R2 = 0.762, F = 80.727*** R2 = 0.729, F = 58.838***
Idio/crypto = idiopathic/cryptogenic; AED = antiepileptic drug; LOS = length of hospital stay.
* P =< 0.05. ** P =< 0.01. *** P =< 0.001.
followed by the drug lamotrigine and CT utilisation.
The only significant predictors of total costs among the
demographic and clinical parameters were epilepsy
type and aetiology. Patients with partial seizures were
associated with lower total costs compared to those
with generalised seizures. Additionally, those with id-
iopathic epilepsy in aetiology were associated with
lower costs compared to those with epilepsy of known
origin (Table 5).
For both in-patients and out-patients, the data also
fit the model well (R2 = 0.729, F = 58.838, P =
0.001). As expected, the length of hospital stay had
the greatest weight followed by the newer drug lam-
otrigine and then specialist visits. The only significant
predictor of total costs among the demographic and
clinical parameters when all patients were aggregated
was age. The relationship was positive; as patients
grew older, total costs increased.
DISCUSSION
The mean estimated annual direct medical cost of
epilepsy for our cohort was US$1432 using a gov-
ernment hospital perspective in year 2000 dollars.
In-patient admission was the most important contrib-
utor to total cost, and accounted for nearly 52% of
the total cost. The second and third most important
predictors of total cost were pharmaceutical use and
specialist visits, which accounted for 22.5 and 13.1%
of the total annual direct medical cost, respectively.
De Zelicourt et al.8 conducted a similar 2-year lon-
gitudinal, prospective cohort study in France in 1998.
The annual direct medical cost in our cohort was lower
than their first year cost (US$1432 vs. US$1954). Like
our cohort, their most significant contributor to total
cost was in-patient care, representing 68% of the to-
tal first year costs. However, their second contributors
were CT scan and MRI use. Despite the fact that our
study’s hospitalisation rate at 8.4% was much lower
compared to theirs (65%), the average length of hospi-
tal stay in our study was much higher (9.0 days vs. 4.5
days). The higher hospitalisation rate in the De Zeli-
court study8 was not surprising as they were follow-
ing only new cases of epilepsy, and thus patients had
to be admitted for the medical work-up. Only around
10% of patients in our study were newly diagnosed.
One possible reason for longer hospital stays in our
study could be due to the nature of the health care sys-
tem in Oman which is offered free to all patients with
no deductibles, co-insurance or co-payments. This can
undoubtedly lead to over-utilisation of health care re-
sources as seen in the earlier days of indemnity insur-
ance in the United States.
Halpern et al.9 analysed the direct medical costs
associated with epilepsy in the United States via a
patient-based approach using the 1987 National Med-
ical Expenditure Survey (NMES). They adjusted the
survey to reflect 1995 values using the Consumer
Price Index (CPI). Their annual direct medical cost
(US$1490) closely mirrored ours (US$1432). Their
most important contributors to total cost were the
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combination of hospital and physician services, AED
use, and diagnostic procedures, which accounted for
51, 24 and 10% of total cost, respectively. Unlike the
French study8, our hospitalisation rate (8.4%) was
similar to the one presented by Halpern et al.9 in the
United States (10.9%).
Our cohort, like that in the study conducted by
De Zelicourt et al.8, showed epilepsy to be evenly
distributed between the sexes. Previous findings in
Oman10 and other studies in the United States11 have
shown epilepsy to be more common in males than
females. The age distribution also showed remarkable
differences with those published elsewhere in Europe
and the USA8, 12, 13. A much younger cohort charac-
terised our study, as only 2.3% of the patients were
65 years of age or older. This is most likely due to the
fact that the Omani population is relatively young.
According to data published by the World Health
Organization14, only 4.1% of Oman’s population is
older than 60 compared to 10% for France, 16.4% for
the USA and 24% for the UK8, 12, 13.
Based on the number of refills, sodium valproate
was the most frequently prescribed AED, followed
by carbamazepine and lamotrigine. Despite represent-
ing only 9.7 and 1.2% of the prescription refills, re-
spectively, multivariate analysis (Table 5) has shown
that the newer drugs, lamotrigine and vigabatrin, are
among the significant predictors of total cost, with
lamotrigine as the second most significant contributor
for both out-patients and in-patients combined. The
annual AED cost per patient (US$321) was similar to
that published recently (US$364) by Halpern et al.9
The authors acknowledge a number of limitations
in this study. In spite of their obvious effective-
ness, there is still some debate15, 16 surrounding the
cost-effectiveness of the newer AEDs and the ques-
tions whether their high cost is offset by reductions
in seizure frequency, health service use, and improve-
ment in functioning and quality of life. Despite the
fact that this study attempted to capture all direct
costs of epilepsy, it was not able to attribute costs as-
sociated with the length of hospital stay itself because
of the particular problem of co-morbidities associated
with epilepsy. Finally, being a tertiary care medical
centre, the annual per patient cost may not be gener-
alisable to the country as a whole as the patients seen
may have more complicated medical problems with
various other co-morbidities.
In summary, this analysis provides the first cost data
for epilepsy treatment in Oman. The results may aid
not only the institution involved, but also the country
as a whole in the appropriate and efficient allocation of
health care resources. The results may also provide a
useful basis for pharmacoeconomic evaluations of in-
terventions, such as those of AEDs. Besides in-patient
admissions, our findings demonstrate that the newer
AEDs, namely lamotrigine and vigabatrin, are signifi-
cant predictors of total costs, and thus any incremental
benefits derived must be rigorously assessed.
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